Avoro Capital Advisors LLC Sells 308,495 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

Avoro Capital Advisors LLC reduced its position in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 8.0% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,541,505 shares of the company’s stock after selling 308,495 shares during the quarter. Kura Oncology comprises about 1.0% of Avoro Capital Advisors LLC’s portfolio, making the stock its 25th biggest position. Avoro Capital Advisors LLC owned 4.65% of Kura Oncology worth $72,920,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. BVF Inc. IL grew its position in shares of Kura Oncology by 9.5% during the 4th quarter. BVF Inc. IL now owns 7,373,228 shares of the company’s stock worth $106,027,000 after buying an additional 642,245 shares in the last quarter. Vanguard Group Inc. grew its holdings in Kura Oncology by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after acquiring an additional 28,212 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Kura Oncology by 10.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,001,754 shares of the company’s stock valued at $28,785,000 after purchasing an additional 197,530 shares during the period. Artal Group S.A. increased its position in Kura Oncology by 8.6% during the 1st quarter. Artal Group S.A. now owns 1,919,884 shares of the company’s stock valued at $40,951,000 after purchasing an additional 151,828 shares during the period. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Kura Oncology by 50.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after purchasing an additional 577,732 shares in the last quarter.

Wall Street Analyst Weigh In

KURA has been the topic of a number of recent research reports. Wedbush reiterated an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a research note on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 target price on shares of Kura Oncology in a research report on Monday, August 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Monday, September 9th. Stifel Nicolaus decreased their price objective on Kura Oncology from $28.00 to $26.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Finally, StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $30.60.

Kura Oncology Stock Performance

Shares of KURA opened at $20.95 on Monday. Kura Oncology, Inc. has a 12 month low of $7.41 and a 12 month high of $24.17. The stock has a fifty day moving average price of $20.25 and a 200-day moving average price of $20.61. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02. The firm has a market cap of $1.60 billion, a PE ratio of -9.65 and a beta of 0.84.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.04. Kura Oncology’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.53) EPS. Equities research analysts predict that Kura Oncology, Inc. will post -2.45 earnings per share for the current fiscal year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.